Skip to main content
. 2015 Oct 16;6(35):38061–38078. doi: 10.18632/oncotarget.5706

Figure 6. CDC25 inhibition relieves differentiation block in FLT3-ITD AML primary cells from patients.

Figure 6

a. 4 primary samples from patients carrying the FLT3-ITD mutation (ITD #1–4) were treated for 6 days with IRC-083864 (100 nM), and the expression of CD14 (upper panel) and CD15 (lower panel) was followed by flow cytometry analysis. b. Quantification (mean ± SEM, n = 4) of CD14 (upper panel) and CD15 (lower panel) expression in response to IRC-083864. c. The morphology of primary cells from patients used in (a) was analyzed by microscopy after 6 or 9 days of treatment with IRC-083864. Original magnification x100.